5 Top Losers In Healthcare Sector (RMED, NMRD, NTRP…)

(RTTNews) - The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

1. Ra Medical Systems Inc. (RMED)

Ra Medical is a commercial-stage medical device company, with a focus on vascular and dermatological diseases.

Lost 57.09% to close Tuesday's (Aug.13) trading at $1.21.

News: The Company reported certain preliminary financial results for the quarter ended June 30, 2019, as well as a leadership transition.

Revenue is anticipated to be between $2.02 million and $2.2 million for the second quarter of 2019, slightly below the consensus analysts' estimate of $2.28 million.

The Company also announced the termination of Dean Irwin from the posts of Chief Executive Officer, Co-President, and Chief Technology Officer, and as Chairman of its Board of Directors. Andrew Jackson, currently serving as Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer.

There is also going to be a delay in the reporting of earnings for the second quarter of 2019 and the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.

2. Plus Therapeutics Inc. (PSTV)

Plus Therapeutics, formerly known as Cytori Therapeutics Inc., is a clinical-stage pharmaceutical company.

Lost 19.64% to close Tuesday's trading at $4.50.

News: No news

Recent event:

A 1-for-50 reverse stock split was implemented and the stock began trading on a split-adjusted basis beginning on August 6, 2019.

3. Nemaura Medical Inc. (NMRD)

Nemaura is a medical technology company developing sugarBEAT, a non-invasive Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics.

Lost 15% to close Tuesday's trading at $0.85.

News: No news

Near-term Catalyst:

Nemaura submitted its De Novo 510(k) Application for SugarBEAT to the FDA in July of this year. An update related to this is expected to be provided later this quarter.

4. Xenetic Biosciences Inc. (XBIO)

Xenetic Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics.

Lost 12.26% to close Tuesday's trading at $1.86.

News: No news

Recent events:

-- On July 22, 2019, the Company announced that it has closed its previously announced $15.0 million underwritten public offering.

About 2.3 million shares of its common stock and warrants to purchase up to 2.3 million shares of the common stock were sold in the offering. Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined price to the public of $6.50 per share and warrant.

-- On June 25, 2019, a one-for-twelve reverse stock split of the Company's issued and outstanding common stock was implemented.

5. Neurotrope Inc. (NTRP)

Neurotrope is a clinical-stage biotech company developing targeted therapeutics for neurodegenerative diseases like Alzheimer's and cognitive diseases and dysfunctions, such as Fragile X. The lead product candidate is Bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina, which is being evaluated as a potential treatment for Alzheimer's.

Lost 11.52% to close Tuesday's trading at $5.30.

News: No news

Near-term Catalyst:

-- A phase II confirmatory study of Bryostatin in over 100 patients with moderate to severe Alzheimer's is underway. The top-line efficacy data from this study is expected to be announced during the third quarter of 2019.